Clinical Trials Browser

tremelimumab × Gastrointestinal × 90 days × Clear all

NCT06855225 2026-04-17

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT07391670 2026-04-17

IMFINZI-subQ

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT06117891 2026-04-15

REFINE-IO

Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT06880523 2026-04-14

SLIDE-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02888743 2026-04-13

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07511504 2026-04-06

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03937830 2026-03-24

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03298451 2026-03-20

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06608940 2026-02-19

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Liver Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05883644 2026-02-18

SIERRA

Phase 3 Active not recruiting

Gastrointestinal

Liver Neoplasms

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT06904170 2026-02-03

ALICE

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

Phase EARLY_PHASE1 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07174570 2026-01-28

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03539822 2026-01-21

CAMILLA

Phase 1/2 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms